Fresh data from the world’s leading HPV congress just rewrote the standard counseling script. If you administer vaccines, read this before your next shift.
What Just Dropped at EUROGIN 2026
Researchers from Denmark, Norway, and Sweden just delivered the strongest long-term HPV vaccine data the field has ever seen.
Long-term follow up data from a pivotal clinical efficacy trial tracked vaccinated women for up to 15.6 years. Within the per-protocol effectiveness population, 1,668 women representing nearly 14,000 person years of follow up, investigators detected zero cases of high-grade cervical disease related to vaccine targeted HPV types. The vaccine effectiveness reached 100% (95% CI, 94.0–100%) over that entire follow up period, with no statistically significant evidence of waning immunity.
Let that sink in. Zero cases. In nearly 14,000 person years of observation.
The FUTURE II Nordic follow-up study added another milestone: the quadrivalent vaccine demonstrated sustained effectiveness through 18 years against HPV 16/18 related high grade cervical disease, supporting decades long immunogenicity.
Paula Annunziato, senior vice president of Infectious Diseases and Vaccines at Merck Research Laboratories, stated: “Nearly two decades after FDA approval of GARDASIL in June 2006, we are proud to present these data for GARDASIL 9 and GARDASIL that reinforce the long-term effectiveness and importance of HPV vaccination for females ages 9 to 45 years, beginning in adolescence.”
This evidence now removes one of the most common hesitations patients and parents raise: “How long does it actually last?” You now have a direct, evidence backed answer.
The Number That Should Reshape Every Male Patient Conversation
Most pharmacists still think of HPV vaccination as a conversation for female patients. This data says otherwise, and loudly.
Each year, more than 18,700 men and 3,800 women receive diagnoses of oropharyngeal cancer in the United States. HPV drives 70% of those cases.
Read that again. Men develop oropharyngeal cancer at nearly five times the rate of women. Yet they receive HPV vaccines far less often.
Unlike cervical cancer, no early screening equivalent to the Pap smear exists for oropharyngeal malignancies. HPV vaccination is the only meaningful prevention tool currently available for these cancers in men.
Carole Fakhry, MD, MPH, professor at Johns Hopkins University School of Medicine, describes oropharyngeal cancer as “epidemic because the rate of growth is so high.” The typical presentation is a painless neck mass, often discovered while shaving, that has already spread to the lymph nodes by the time someone notices it.
The treatment is brutal: surgery, radiation, chemotherapy, or some combination. The prevention? A three-dose series you stock and administer every day.
The FDA granted GARDASIL 9 accelerated approval for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58. The vaccine covers males and females ages 9 through 45 years.
Where the US Still Falls Short
Globally, momentum around HPV vaccination keeps building. By late 2025, 159 countries, representing 82% of WHO member states, had introduced HPV vaccines into their national programs, covering an estimated 64% of the global population of girls aged 9 to 14.
The United States, however, lags behind where it should be. As of 2024, 78.2% of eligible adolescents aged 13 to 17 had received at least one dose. Only 62.9% completed the full series, still below the Healthy People 2030 target of 80% series completion.
The gap across states is staggering. Series completion rates range from 79.8% in Massachusetts down to 39.1% in Mississippi.
That 40-point spread represents real cancers that will develop in real people over the next two decades, largely preventable cancers. Male patients account for a disproportionate share of those gaps, because the vaccine conversation still rarely reaches them.
Your Role as the Most Accessible Provider in the Room
Consider what happens when a patient shows up for a flu shot, a shingles vaccine, or a travel immunization. You scan their record. You prepare the injection. You have 90 seconds of face time with someone who trusts you.
That 90 seconds carries more clinical impact than most providers realize.
Pharmacists can improve HPV vaccine access by verifying vaccination status, administering 2- or 3-dose schedules based on age, and reinforcing the continued need for cervical cancer screening even in vaccinated patients.
The counseling script for male patients is simpler than most pharmacists expect. You don’t need to lead with HPV. Lead with cancer prevention. The moment a 35-year-old man hears “this vaccine prevents throat cancer in men,” the conversation changes.
That framing, cancer vaccine for men, not just women, drives uptake. The data on oropharyngeal cancer is now too strong to leave on the table.
Your Clinical Checklist Starting Today
Every time you administer any vaccine to a male patient between 9 and 45 years old, add these three steps:
1. Check their HPV vaccination record. Most adult male patients never started the series. Many have no record at all.
2. Frame it as cancer prevention. Say: “This vaccine prevents throat cancer, which is now more common in men than cervical cancer is in women. Would you like to start the series today?” That is an accurate, evidence-based statement that lands.
3. Know your dosing schedule. Ages 9–14 require two doses (0 and 6–12 months). Ages 15–45 require three doses at 0, 2, and 6 months. You can start the series on the spot during any visit.
The Bottom Line
Twenty years of data now back what we suspected from the start. The 9-valent HPV vaccine provides protection that lasts at least 14 years, and likely far longer, with no meaningful evidence of waning immunity in the per-protocol population.
The evidence base just grew. The oropharyngeal cancer burden in men is now undeniable. And the access gap in the United States remains one of the most solvable problems in preventive care, if pharmacists decide to own it.
You are the most accessible healthcare provider most of these patients will see this year. Use the 90 seconds.
Sources: Pharmacy Times (EUROGIN 2026 HPV Vaccine Data Coverage), Contemporary OB/GYN (EUROGIN 2026 Merck Presentation), Merck Press Release (EUROGIN 2026), AAMC (HPV Cancers Are Rising, January 2026), CDC (Cancers Associated with Human Papillomavirus, December 2025), KFF (HPV Vaccine Access and Use in the US), PMC / National Immunization Survey-Teen (2024 Vaccination Coverage Data), Journal of Vaccines (Global Status of HPV Vaccination, 2025)
